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The leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4, also called GPR48) plays a key role in multiple
developmental processes, and mice lacking Lgr4 display anterior segment dysgenesis leading to early-onset glaucomatous retinal
ganglion cell loss as well as defective eyelid formation. This paper will review Lgr4 signaling and its regulation of the Axenfeld-
Rieger syndrome gene Pitx2, a crucial developmental transcription factor. In addition,Wnt signaling plays an important role in eye
development, with Norrin functioning to activate the Wnt receptor Frizzled 4 required for proper retinal vascularization. Recent
discoveries identifying Lgr4 as a receptor for Norrin highlight the potential for Lgr4 function in retinal vascularization. Finally,
several unanswered questions impeding a full understanding of Lgr4 in glaucoma are considered as avenues for further research.
1. Introduction
Glaucoma is the second leading cause of blindness world-
wide, but its etiology is complex and only partially under-
stood. Frequently associated with elevated intraocular pres-
sure (IOP) leading to a stereotypical pattern of retinal
ganglion loss and cup excavation, glaucoma may result from
closure of the iridocorneal angle, blockage of the trabecular
meshwork responsible for aqueous humor outflow, pupil
block of the space between the lens and iris necessary
for humor circulation between the anterior and posterior
chambers, and several other causes. Loss of the leucine-
rich repeat domain-containing G protein-coupled receptor
4 (Lgr4, also called Gpr48) has been implicated in anterior
segment dysgenesis including iridocorneal attachment and
elevated intraocular pressure leading to early onset retinal
ganglion cell loss inmice that is similar to glaucomatous dam-
age in humans [1]. Recently published work identifies Lgr4 as
a receptor forNorrin, a secreted proteinwith established roles
in retinal neuron protection and retinal vascularization and
therefore suggests an additional mechanism by which Lgr4
functions to prevent glaucoma [2].This paper will provide an
overview of Lgr4 signal transduction and its role in a wide
variety of developmental processes, followed by a focus on
recent developments in the role of Lgr4 in glaucoma.
2. Lgr4 Signaling
The leucine-rich repeat domain-containing G protein-
coupled receptors (LGRs) feature a large N-terminal
extracellular domain containing multiple leucine-rich
repeats and are subdivided into three groups. One group
consists of the three glycoprotein hormone receptors:
lutenizing hormone receptor, follicle-stimulating hormone
receptor, and thyroid stimulating hormone receptor. The
second group contains LGR4–6, three receptors sharing high
homology (∼50% sequence identity) that were recently found
to act as receptors for the Wnt-potentiating R-spondins,
indicating that this group can signal through both G protein-
coupled as well as Wnt-signaling pathways. The third group
is comprised of the relaxin receptors LGR7 and 8.
Lgr4 has been shown to signal through classical G
𝛼s-
mediated signaling in multiple systems. In this pathway
(Figure 1), ligand binding to Lgr4 leads to G-protein acti-
vation through GTP binding. Coupled G
𝛼s then dissociates

























Figure 1: Signaling pathways downstream of Lgr4. Left: binding of unknown ligands (?) leads to G
𝛼s activation of adenylyl cyclase (AC) and
resulting increase in intracellular cyclic AMP levels (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB
inducing its nuclear translocation and regulation of CRE target genes such as Pitx2. Right: Norrin or R-spondin (Norrin/RSPO) binding
to Lgr4 augments the response of Frizzled (Fzd) and LRP5/6 to Wnt binding, leading to activation of Disheveled (DSH). DSH blocks the
GSK3/Axin2/APC-mediated degradation of 𝛽-catenin (𝛽-cat), allowing 𝛽-catenin accumulation and nuclear translocation (dashed arrow)
where 𝛽-cat binds TCF/LEF (TCF) family transcription factors to regulate Wnt target gene expression. Dikkopf (Dkk) is a competitive
inhibitor of Wnt binding to Fzd.
from Lgr4 to activate adenylyl cyclase resulting in ele-
vated levels of the second messenger cyclic AMP (cAMP);
cAMP, in turn, activates protein kinase A (PKA), which
phosphorylates the transcription factor Cre-binding protein,
leading to elevated expression of target genes containing
CRE binding motifs in their promoter. Known Lgr4 targets
regulated through cAMP/PKA/CRE signaling include the
mineralocorticoid receptor [3], estrogen receptor 𝛼 in the
male reproductive tract [4], ATF4 in bone development and
definitive erythropoiesis [5, 6], and Pitx2 in eye development
[1]. Significantly, the ligand(s) initiating cAMP/PKA signal-
ing by Lgr4–6 remains unidentified.However, a constitutively
active mutant, T755I Lgr4, has been reported which results in
elevated cellular cAMP levels and CREB activity [1, 7].
The Lgr4 family members Lgr5 and 6 have been impli-
cated in stem cell maintenance in a variety of tissues. Lgr5 is
a stem cell marker in the small intestine [8], stomach [9], liver
[10], hair follicle [11], and, most recently, mammary gland
[12, 13]. Lgr6 marks the most primitive kind of epidermal
stem cell [14]. A single Lgr5 expressing colon cell was able to
generate organoids that persist in culture and can engraft to
form functional crypts in vivo [15]. Conditional loss of Lgr5
leads to depletion of stem cells in the mammary gland [12],
implying that Lgr5 signaling has a functional role in stem
cell self-renewal. The most likely mechanism for this role is
by a second signal transduction pathway: Lgr mediation of
Wnt signaling potentiation by R-spondin. R-spondin binding
to LGR4–6 inhibits ZNRF3 and RNF43, negative regulators
of Wnt signaling which promote degradation of the Wnt
receptor Frz and theWnt coreceptors LRP5/6 [16].Thus, Lgr4
and its family members function to increase the membrane
concentration ofWnt receptors in the presence of R-spondin,
enhancing the signaling response to low levels of Wnt ligand.
An alternative mechanism for R-spondin signaling has also
been proposed, inwhich R-spondin-bound Lgrs bind directly
to LRP6 to augment LRP6 phosphorylation in response to
Wnt-Fzd binding [17]. Clathrin was also reported to be
required for Lgr4 mediation of R-spondin in vitro [18]. Most
recently, Lgr4 was shown to be a receptor for Norrin, another
canonical Wnt signaling potentiator [2], providing another
means by which Lgr4 modulates Wnt signaling.
3. Lgr4 in Development
Lgr4 mRNA expression in mice was first detected at E7 and
in adult mice was the highest in liver, then kidney, with
moderate expression in muscle, heart, and brain, and low
levels in testes and lung [19]. Mazerbourg et al. (2004) [20]
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first described the mouse expression pattern of Lgr4 protein,
using both IHC staining of wild-type tissue as well as
transgenic mice expressing 𝛽-galactosidase from the Lgr4
promoter. They noted moderate Lgr4 expression in neonatal
kidney, adrenal, stomach, spine, ribs, brain, nasal cavity,
heart, and intestines, with lower levels in liver, lung, and
spleen. No Lgr4 was detected in skeletal muscle or pancreas.
Adults had a very similar pattern of Lgr4 expression, with
reduced heart Lgr4 and higher liver levels; also, no lung or
spleen expression was detected in adult Lgr4+/− [20]. Lgr4
mRNA expression in adult humans is the highest in the
pancreas, withmoderate levels in liver, heart, andmuscle, and
very low brain and kidney expression [19].
Two approaches have been used by different labs to
generate Lgr4−/− mice. In one approach, a gene trap cassette
was inserted in the first intron to generate a chimeric mRNA
containing the N-terminal Leucine-rich repeat of Lgr4 fused
to the CD4 transmembrane domain and the 𝛽-galactosidase
coding sequence [1, 20].This approach showed that Lgr4 is an
essential gene for embryonic development; 60% of expected
Lgr4−/− pups died in utero, and the majority of remaining
Lgr4 null pups died perinatally in a C57Bl6J X Swiss Webster
background; modest (∼10%) declines in expected numbers of
Lgr4+/− mice were also reported [20]. Lgr4−/− pups showed
embryonic growth retardation (14% decrease in Lgr4−/−
neonatal pup weight), with a significant decrease in liver and
kidney weight [20]. Background strain has a strong effect on
the embryonic and perinatal survival of Lgr4−/− mice, with
higher lethality in 129Ola x C57Bl6 mice [21], but 60% of
Lgr4 null mice on a CBA background survive [22]; most
CD1 strain Lgr4−/− mice also survive to adulthood [23].
The alternative approach is to perform targeted knockout of
Lgr4 exon 18, containing the seven-transmembrane domain.
This approach revealed a similarly high level of embryonic
lethality, with embryonic kidney hypoplasia [21], later shown
to be accompanied by premature ureteric bud differentiation
[24].
A wide variety of developmental defects have been
reported in Lgr4−/− mice. In addition to the embryonic
lethality and decreased growth noted above and the eye
defects discussed below, midgestational erythropoiesis is
disrupted in Lgr4−/− embryos, with a 32% decrease in Ter119+
cells at E13.5 as compared to wild type [6]. Lgr4 loss delays
osteoblast differentiation, resulting in decreased embryonic
bone formation; bone formation kinetics and bone mineral
density were decreased through adulthood in Lgr4−/− mice
[5]. Lgr4−/− mice also lack a gall bladder and cystic duct,
although the common hepatic duct and intrahepatic bile duct
appeared unchanged [25]. Lgr4 regulates expression of the
mineralocorticoid receptor, implicating Lgr4 in electrolyte
homeostasis [3]. Both male [4, 22, 23, 26] and female [27]
reproductive tract formation is impaired in Lgr4−/−, leading
to infertility in homozygous null mice. Intestinal epithelial
cell proliferation was reduced in Lgr4−/− mice, with an 80%
decrease in crypt Paneth cells, suggesting that Lgr4 plays a
crucial role in intestinal stem cell maintenance [28]; Lgr4 also
appears to play a protective role against inflammatory bowel
disease [29].
Conditional knockout approaches have also been used to
avoid the embryonic lethality of Lgr4 loss and have revealed
additional developmental phenotypes. Mice with specific
ablation of Lgr4 in cells expressing keratin 5 showed focal
alopecia and fewer hair placodes, implicating Lgr4 action in
hair follicle development [30]. Loss of Lgr4 in keratin 5+ cells
also disrupted mammary gland branching morphogenesis
and delayed ductal elongation [31] and was proposed to
impair oviduct function in promoting embryo development
[27]. Therefore, Lgr4 is a key regulator of organ development
in a wide variety of extraocular systems.
3.1. Lgr4 in Eye Development. Lgr4 is normally expressed
in a finely tuned spatiotemporal pattern in the developing
eye. Using Lgr4-driven 𝛽-galactosidase expression to probe
for Lgr4 expression in Lgr4 heterozygotes, we found that at
E12.5, Lgr4 is primarily expressed in a layer of mesenchymal
cells between the surface ectoderm and the optic cup; limited
expression is also detectable in the lens and the outer
layer of the optic cup (Figure 2). By E16.5, high-level Lgr4
expression is seen in the tips of the optic cup and surrounding
mesenchyme, which later form the iris and ciliary body,
with lower levels in the cornea, retina, and lens. Neonatal
mice retain strong expression in the ciliary body, iris stroma,
lens, and corneal epithelial cell layer, with lower expression
in keratocytes and endoepithelial cells. Adult Lgr4+/− mice
express Lgr4 in the lens epithelium, retinal ganglion and
inner nuclear layer, iris stroma, and outer ciliary body cell
layer [1].
Using the gene trap approach described above, we gen-
erated Lgr4−/− mice which had multiple ocular defects. 25
out of 47 Lgr4−/− mice had microphthalmia, with a much
higher incidence in males (75%) compared to females (37%),
suggesting that Lgr4 interacts with a sex-linked factor in this
phenotype [1]. Partial corneal opacity, usually accompanied
by corneal neovascularization, was present in 18 of 47 mice.
A variety of keratopathies (corneal epithelial plug, corneal
inflammation, corneal cyst-like structures, and corneal vas-
cular pannus) were each found in 4 or more mice, with a
higher frequency in male mice [1]. Cataracts formed in 13 of
47 Lgr4−/− mice, which were correlated with higher levels of
insoluble 𝛼A-crystallin in the lenses of Lgr4−/− mice.
Furthermore, Lgr4 plays an essential role in eyelid devel-
opment. 85% of Lgr4−/− mice had a failure of eyelid fusion
in utero leading to eye open at birth, and adult Lgr4−/− mice
exhibited exposure keratitis [32]. In a separate paper using
an Lgr4 exon 18 deletion, Lgr4−/− mice had complete eye
open at birth penetrance, but these mice did not survive to
adulthood [33]. Lgr4 is normally expressed in the eyelid tip
basal epithelium andmesenchyme at E14–E16. Lgr4−/−mouse
eyelids were morphologically similar to those of Lgr4+/+ at
E12.5 but had decreased eyelid epithelial cell proliferation.
Eyelid extension towards the corneal center was noticeably
decreased by E15.5 in the absence of Lgr4 [33], with fewer
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Figure 2: Temporal and spatial expression of Lgr4 inmouse eyes. (a) Expression of Lgr4 at embryonic day E12.5 using𝛽-galactosidase staining
in Lgr4 heterozygous (+/−) and wild-type control (+/+) mice. (b) Expression of Lgr4 at postnatal day 0 (P0). Scale bar = 170𝜇m. (c) Temporal
expression of Lgr4 during different stages of anterior segment development. At E12.5 days, Lgr4-expressing mesenchymal cells are located
between the surface ectoderm and the lens and the inner layer cells of the optic cup. At E16.5–E18.5, Lgr4 expression is high at the tips of
the optic cup and in the surrounding mesenchymal tissue. In newborn embryos, Lgr4 is highly expressed in the iris stroma, ciliary body,
corneal epithelium, keratocytes, and endoepithelial cells. Wild-type (+/+) mice lack expression of 𝛽-galactosidase. Scale bars = 170𝜇m. (d).
Expression of Lgr4 in adult mouse tissue. Staining was found in lens epithelial cells, retinal ganglion cells, inner nuclear layer, iris stroma, and
the outer layer of the ciliary body. C: cornea; I: iris; R: retina; L: lens; CB: ciliary body; G: ganglion cells; IN: inner nuclear layer; ON: outer
nuclear layer. Scale bars = 85𝜇m. Originally published PNAS 105(16): 6081-6. Copyright 2008 National Academy of Sciences USA.
filopodia [32]. Cultured Lgr4−/− keratinocytes had decreased
migration [33] and proliferation and decreased phospho-
EGFR, suggesting that Lgr4 regulates EGFR activation [32].
Inhibition of EGFR reduced keratinocyte proliferation and
migration to levels seen in Lgr4−/− cells, and inhibitory anti-
bodies against HB-EGF also reduced wild-type keratinocyte
proliferation to Lgr4−/− levels, suggesting that Lgr4 may acti-
vate EGFR signaling in keratinocytes through upregulation of
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metalloproteases that generate HB-EGF; however, this model
awaits confirmation in vivo [34].
Finally, anterior segment dysgenesis (ASD) was common
in mice lacking Lgr4. Lgr4−/− mice displayed iris hypopla-
sia with decreased stroma and smooth muscle as early as
postnatal day 4, diminished ciliary body size and folding,
compressed trabecular meshworks with fewer and smaller
beams, and a sharper iridocorneal angle that in some cases
(13%) was completely closed. Lgr4−/− retinas had detectable
loss of inner nuclear layer ganglion cells and disruption of the
outer nuclear layer beginning at 6 months of age in 42% of
mice examined (10 of 24), strongly implicating ASD resulting
from Lgr4 loss in early-onset glaucoma [1]. Several lines
of evidence implicate the Axenfeld-Rieger syndrome-related
genePitx2 as a keymediator of Lgr4 in eye development. First,
the ASD phenotype in Lgr4−/−mice closely matches that seen
in Pitx2+/− mice, including iris hypoplasia and periocular
musculature defects. Second, Pitx2 was the only transcription
factor out of a panel of fourteen key eye development genes to
be downregulated in Lgr4−/− mice. Finally, Pitx2 was shown
to be a direct downstream target of Lgr4 signaling through
the cAMP/PKA/CREB pathway [1].
4. Pitx2 and Axenfeld-Rieger Syndrome
Axenfeld-Rieger syndrome (ARS) is a rare genetic disease
generally with autosomal dominant inheritance charac-
terized by ocular disorders (potentially including iris hypo-
plasia, corectopia, pseudopolycoria, posterior embryotox-
on, and iris strands connecting to the trabecular mesh-
work or other angle structure anomalies) resulting in ele-
vated intraocular pressure, sometimes accompanied by
craniofacial abnormalities (telecanthus, hypertelorism) or
dental defects (small or missing teeth). ARS patients have a
high risk for glaucoma [35]. Cardiovascular abnormalities
are also reported in ARS patients [36–39], as well as hearing
loss in some cases [36, 40]. Mutations in either PITX2 or
FOXC1 have been estimated to account for 40% of ARS cases
[35, 41–45]. Pitx2 is a paired-like homeodomain transcription
factor. Mice heterozygous for Pitx2 display multiple anterior
segment defects similar to ARS, including corneal endoderm
and iris stroma agenesis, corneal mesothelial thickening,
coloboma formation, and shortened ventral retina, and
Pitx2−/− mice are embryonic lethal due to incomplete
closure of the ventral body wall [46, 47]. Loss of extraocular
musculature has also been reported in Pitx2 heterozygotes,
with a more severe phenotype in Pitx2−/− mice [48]. Pitx2 is
normally expressed in the neural crest during development
beginning at E9.5, as well as in the developing eye mesoderm,
hyaloid space, and eyelid mesenchyme [49, 50]. There is
a strong dosage dependence of Pitx2 for proper devel-
opment; transgenic mice overexpressing PITX2A in the
corneal mesenchyme and iris show corneal hypertrophy,
corneal opacification, iridocorneal attachments, and retinal
degeneration [51]. Intriguingly, a downstream target of Pitx2
is the Wnt-signaling antagonist Dkk2, which plays a crucial
role in regulating anterior segment morphogenesis [52].
5. Norrin and Wnt Signaling in
Eye Development
Canonical Wnt/𝛽-catenin signaling plays an essential role in
development and in tissue homeostasis. Key components of
the pathway are the Wnt proteins, a family of 19 secreted
glycoproteins, the Frizzled (Fzd) receptors, which are seven
membrane-spanning receptors for Wnt, and the Wnt core-
ceptors LRP5 and 6. Wnt binding results in activation
of the downstream transducer Dishevelled (Dsh), which
phosphorylates glycogen synthase kinase 3 (GSK-3) resulting
in inactivation of the Axin/APC complex that normally
ubiquitylates 𝛽-catenin (Figure 1). As a consequence, 𝛽-
catenin accumulates and translocates to the nucleus, where
it associates with Tcf/Lef transcription factors to regulate
gene transcription. Negative regulators of Wnt signaling
include the Dikkopf (Dkk) and secreted Frizzled-related
proteins (sFRP) which bind to Frz or Wnt, respectively, to
inhibit cascade activation. Loss of 𝛽-catenin in the periocular
ectoderm results in ectopic lentoid body formation whereas
presumptive lens ectoderm expression of dominant active
𝛽-catenin suppresses lens development [53], suggesting that
low levels of 𝛽-catenin signaling are required for proper
lens formation. Ectoderm-specific active 𝛽-catenin expres-
sion disrupts optic cup patterning resulting in a lack of
cornea, conjunctiva, and eyelid development [54]. Dkk2−/−
mice display a transformation of corneal epithelium into a
stratified epithelium [55], iridocorneal adhesion, eye open at
birth phenotype with hypomorphic eyelids and ectopic hair
follicles in the presumptive conjunctiva, and ectopic corneal
stroma vasculature [52]. Therefore, proper spatiotemporal
control of Wnt/𝛽-catenin pathway signaling intensity is
essential for anterior segment development.
In addition to playing a crucial role in anterior segment
development, Wnt signaling was reported to have a signifi-
cant ongoing function in trabecular meshwork (TM) cell reg-
ulation. RNA differential display of cultured human TM cells
identified elevated expression of the Wnt antagonist secreted
Frizzled-related protein 1 (sFRP1) in cells from glaucomatous
donors, and perfusion of sFRP1 into cultured human eyes
resulted in decreased canonical Wnt signaling and reduced
aqueous outflow. Intraocular injection of adenoviral vectors
to express sFRP-1 in BALB/c mice resulted in a twofold
increase in intraocular pressure (IOP), an increase that was
partially reversible through topical application of a GSK-
3 inhibitor, suggesting that sFRP-1 increased IOP through
inhibiting canonical Wnt/𝛽-catenin signaling [56].
Intriguingly, Pitx2 had been reported to be a direct Wnt
target gene in culture [57, 58], and Dkk2−/− mice have
elevated Pitx2 expression in the corneal stroma, suggesting
the existence of a negative feedback loop regulating Pitx2
expression during eye development [52]. We speculate that
Lgr4 may play a crucial role in integrating these signaling
circuits, as Lgr4 binding to R-spondin potentiatesWnt signal-
ing, leading to Pitx2 expression, and activation of G protein
signaling through a binding of an unknown ligand to Lgr4
results in Pitx2 activation and resulting Dkk2 expression,
which then inhibits Wnt signaling even in the presence
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of both R-spondin and Wnt. Whether the failure of this
signaling circuit is responsible for the ocular defects in
Lgr4−/− mice remains to be determined.
5.1. Norrin in Retinal Vascularization and Function. Norrin
has been shown to enhance Wnt signaling in vitro and to
selectively bind to the Wnt receptor Fzd4 with high affinity
to activate canonicalWnt/𝛽-catenin signaling [59].Mutations
in the NDP gene encoding Norrin result in Norrie disease,
an X-linked congenital syndrome characterized by retinal
vascularization failure leading to blindness, often accompa-
nied by microcephaly, deafness, hypogonadism, or mental
retardation. Familial exudative vitreoretinopathy, a less severe
disruption in peripheral retina vascularization, can also be
caused by mutations in NDP, or alternatively by mutations
in Fzd4 or LRP5. Loss of the mouse homologue, Ndp, causes
defects in retinal vasculature which lead to blindness as well
as cochlear vasculature, and results in female infertility due to
defects in decidualization [59–63]. Curiously, a similar defect
in retinal vascularization has been reported in mice lacking
the Wnt receptor Fzd4 [59] or coreceptor Lrp5 [64]. Norrin
has very recently been reported to be a ligand for Lgr4–
6, suggesting that it plays a role in Wnt signal potentiation
similar to that played by R-spondin family members [2].
Norrin is normally expressed by Mu¨ller glial cells of the
mouse retina [65]; however, retinal vascularization defects
in Ndp𝑦/− mice are overcome by lens-specific expression
of Norrin [66], implying a paracrine mode of action that
does not require spatial concentration gradient formation.
Systemic Norrin overexpression is embryonic lethal, marked
by defective angiogenesis, but can be rescued on either an
Fzd4−/− or an Lrp5−/− background [65]. Retinal pigment
epithelial cell expression of Norrin ablated the extent of
oxygen-induced retinopathy in young (P7–11) mice, implying
a protective effect of Norrin on retinal vasculature [67].
Curiously, inhibition of Fz4 signaling reduced the recovery
from oxygen-induced retinopathy [68]. Angiopoetin-2, an
angiogenic growth factor expressed in the retinal microvas-
culature endothelium, has been proposed to be a downstream
mediator of Norrin’s role in angiogenesis, based on (1) a
similar defect in retinal vascularization in Ang-2−/− mice,
(2) evidence for Norrin regulation of Ang-2 expression in
vivo, and (3) loss ofNorrin-induced increased endothelial cell
proliferation in the presence of Ang-2-blocking antibodies
[67, 69, 70].
In addition to the retinal vascularization defects, Ndp𝑦/−
mice exhibit a loss of retinal ganglion cells (RGCs), with
concomitant decrease in normal retinal function [60, 61, 66].
Lens-specific transgenic expression of Norrin increased RGC
proliferation and resulted in thicker retinas in mice two days
postnatal [66]. Norrin has also been reported to have a neu-
roprotective effect on retinal ganglion cells. Ocular injection
of Norrin reduced the extent of RGC apoptosis and axon
loss following NMDA injection [71], which is in agreement
with a report demonstrating antiapoptotic effects of Norrin
on a cultured RGC cell line [72].The RGC protective effect of
Norrin was partially mediated through induction of several
growth factors (including fibroblast growth factor 2, ciliary
neurotrophic growth factor, and brain-derived neurotrophic
growth factor) by Mu¨ller cells, and partly through a direct
effect of Norrin on RGCs [71]. Intriguingly, no activation
of canonical Wnt/𝛽-catenin signaling was detected in RGCs
following Norrin treatment, suggesting that Norrin acts
through a yet-undiscovered signal transduction pathway to
prevent excitotoxicity in RGCs. Given the recent finding that
Lgr4 is able to bind Norrin [2], this leads to the speculation
that this neuroprotective effect of Norrinmay bemediated by
G protein-coupled signaling downstream of Lgr4.
6. Future Directions
In summary, there is strong evidence that Lgr4 is a key
regulator of Pitx2 in anterior segment formation and that
disruption of this signaling network can result in early-onset
glaucoma in a mouse model. Furthermore, tantalizing new
evidence suggests that Lgr4 functioning as a receptor for
Norrin may be implicated in retinal vascularization and/or
other functions of Norrin, such as retinal neuron protection
from damage. However, a host of critical questions remain.
First, what is the endogenous ligand activating Lgr4 signaling
through the cAMP/PKA pathway resulting in regulation of
Pitx2 and multiple other downstream targets? Identification
of this unknown Lgr4 activator is essential for mapping the
spatiotemporal profile of Lgr4 activity during development
and may serve as a starting point for designing small-
molecule agonists or inhibitors for potential therapeutic use.
Second, which Norrin functions are mediated by Lgr4 or
its close family members? Could Norrin be the unknown
sex-linked factor responsible for the higher incidence of
microphthalmia in male Lgr4−/− mice? Deciphering the
relative importance of classical G protein-coupled versus
Wnt/𝛽-catenin signaling in Lgr4 function remains to be
unraveled.
A third unresolved question concerns additional func-
tions of Lgr4. An area of particular therapeutic interest is
the use of stem cells for glaucoma treatment. Some evidence
exists suggesting the existence of stem or progenitor cells
in the region of Schwalbe’s line (called by several names
including Schwalbe’s line cells, trabecular meshwork insert
cells, and progenitors for endothelium and trabeculum, and
functionally assayed using sphere formation in vitro; see
[73] for an excellent review). Given the roles of Lgr5 and
Lgr6 in stem cell self-renewal in a wide variety of tissues,
together with the established function of R-spondin (and
Norrin) to potentiate Wnt signaling through Lgr4–6, we
speculate that Lgr4 or its family members may play a key
role in maintenance of stem/progenitor cells in this region.
Understanding such a role will be vital in progress towards
using stem cells to regenerate a blocked trabecular meshwork
as an approach towards relieving intraocular pressure.
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